• Armughan Aymen Mastan
• Syeda Zareen Sabira,
• K. Rama Rao
• Anupama Koneru.

In today's stressful world, drugs with neuroprotective and neuropharmacological action that improve brain learning and memory function are desperately needed. Importantly, stress has been shown to impair cognitive abilities, causing the memory to deteriorate rather than learning to progress1. For researchers, mental diseases have long been a source of disinterest, and treating them has always been difficult. Dementia, or memory loss, has captivated the human population all over the world, and it has become a hot topic of research. Human memory is known to decline with age2. Science and medical technology have now made it possible to augment humans in a variety of ways. The possibility of improving our cognitive performance has recently become both innovative and substantial. There are currently several supplements available, such as caffeine for staying awake and DHA for improved memory. However, the latest treatments for improving our cognitive abilities, known as smart pharmaceuticals, are nothing like these supplements. Smart medicines are man-made synthetic substances that have been produced to increase human cognitive abilities. They were originally designed for medicinal purposes, but they can also benefit healthy people. The study of how drugs might improve human intellect began in the nineteenth century3. Cognitive dysfunction is one of the most functionally destructive aspects of many neuropsychiatric and neurodegenerative illnesses, including schizophrenia, depression, Alzheimer's disease, dementia, cerebrovascular impairment, seizure disorders, head injury, and Parkinsonism. By impairing long-term potentiation (LTP) induction and synaptic plasticity, aging plays a significant role in the development of cognitive dysfunction such as age-related memory impairment (AAMI). Our mental abilities are controlled by the brain, which is the organ in charge of them. All of our ideas, emotions, desires, perceptions, learning and memory, curiosity, and behavior are built on this basis. We are restricted to fundamental reflexes and stereotyped reactions without memory, which is a distinct mental activity.4 Alzheimer's disease is the primary cause of dementia in the elderly, affecting an estimated 15 million individuals globally. With the proportion of aged persons in the population steadily growing, the disease's impact on treatments and national economies is predicted to grow significantly over the next two to three decades5. The most significant risk factor for Alzheimer's disease is growing older. AD affects 7% of those aged 65 to 74, 53% of people aged 75 to 84, and 40% of people aged 85 and more. 3 Although other variables may play a role, genetic inheritance is a substantial risk factor. The factors that determine the age of start and the pace of progression are mostly unknown. After the beginning of symptoms, survivors are expected to live for 3 to 20 years, with an average of 8 years. Individuals with Alzheimer's disease live around half as long as others of the same age who do not have the disease. In the United States, Alzheimer's disease is the sixth greatest cause of mortality disease. Although Alzheimer's disease does not directly cause mortality, it does put patients at risk for sepsis, pneumonia, choking and aspiration, nutritional deficits, and trauma6.

NEUROPROTECTIVE AND ANTIOXIDANT ACTIVITY OF BIXA ORELLANA AGAINST SCOPOLAMINE-INDUCED MEMORY IMPAIRMENT IN ANIMAL MODE.

"NEUROPROTECTIVE AND ANTIOXIDANT ACTIVITY OF BIXA ORELLANA AGAINST SCOPOLAMINE-INDUCED MEMORY IMPAIRMENT IN ANIMAL MODE.", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.9, Issue 9, page no.b1-b47, September-2022, Available :http://www.jetir.org/papers/JETIRTHE2016.pdf

"NEUROPROTECTIVE AND ANTIOXIDANT ACTIVITY OF BIXA ORELLANA AGAINST SCOPOLAMINE-INDUCED MEMORY IMPAIRMENT IN ANIMAL MODE.", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.9, Issue 9, page no. ppb1-b47, September-2022, Available at : http://www.jetir.org/papers/JETIRTHE2016.pdf